Partnerships

Circular Biobased Europe

Circular Biobased Europe

Partnership website: https://www.cbe.europa.eu/

The objective of the initiative is to produce major contributions to the climate targets by 2030, pave the way for climate neutrality by 2050, and increase sustainability and circularity of production and consumption systems in line with the European Green Deal.

It aims to develop and expand the sustainable sourcing and conversion of biomass into bio-based products focusing on multiscale biorefinery processing and apply circular economy approaches such as utilisation of biological waste from agriculture, industry and municipal sectors. It also aims to deploy bio-based innovation at regional scale with the view to revival of rural and marginal regions.

The partnership was established by the Council regulation (EU) 2021/2085 of 19 November 2021 

Contact

Commission services: Marton Keri

Partners: Biobased Industries Consortium (BIC) Dirk CarrezPartnership website

What are partnerships?

Partnerships group the EC and private and/or public partners, to coordinate and streamline the research & innovation initiatives and funding in some selected key domains.

How to use partnerships?

  • orientation
    Partnerships publish strategic documents, e.g. outlining the main research and innovation challenges or key focus points.
  • networking
    Partnerships often organise events, such as info days, brokerage events, etc. Meet potential partners and learn about the nuances that are not visible in the official documents.
  • ecosystem analysis
    Partnerships typically have an advisory board, and publish impact studies of previous actions. These are good sources of information to uncover the main R&D&I players in the domain.
  • steering the agenda
    Partnerships collaborate with the EC on outlining the strategy and the future funding opportunities in their domain, based on input from industry, academia, and other stakeholders.

Testimonial

image of Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.